The project
Pancreatic cancer is often diagnosed late. Many people develop diabetes before cancer diagnosis, but this warning sign is usually missed because it looks like common type 2 diabetes. By studying thousands of proteins in blood samples from people with diabetes, pancreatic disease, and healthy individuals, we identified proteins linked to cancer related diabetes. Because no single protein works for everyone, our next step is to find the best combination of proteins that can tell cancer related diabetes apart from type 2 diabetes early enough to allow meaningful treatment.
What are you going to do?
Our health-economic modelling suggested a two-stage blood test approach. First, Dr Eithne Costello aims to identify people whose diabetes is likely caused by pancreatic damage rather than typical type 2 diabetes. Second, within this group, they aim to spot signs of pancreatic cancer while ruling out other pancreatic diseases. To do this, they will test and combine promising blood proteins using several large UK and international patient datasets, including samples taken years before diagnosis. This helps ensure the tests are reliable and can detect cancer early enough to make a real difference
Why is this research important?
Earlier diagnosis is key to improving survival from pancreatic cancer. By identifying the people with new onset diabetes who are most at risk, this research could allow targeted testing and earlier diagnosis, giving patients a better chance of receiving effective treatment. This approach avoids unnecessary screening, improves chances of successful treatment, and could ultimately save lives and reduce the burden of advanced disease.
How do I get involved?
Dr Eithne and her team would welcome the input of anyone affected by pancreatic cancer including patients, survivors, carers and loved ones.
No scientific background or prior experience is needed to take part in this opportunity.
Next steps
If you are interested in joining the focus groups or would like more information, please email Eithne (ecostell@liverpool.ac.uk) quoting the involvement reference ‘RIN Participation’.
